the concern I have is that on May 1 they stated that the Teva portfolio was broadly in line with expectations, that being EBITDA of 6 times acquisition price, I have that at $109m.
now today they are forecasting EBITDA on Teva of $94.5m, that seems a very steep drop off in two months?
I'm happy to be corrected, quick calcs on my part.
Fundamentals Are Strong, page-600
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.48 |
Change
0.000(0.00%) |
Mkt cap ! $381.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17 | $4.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.26 | 1 | 1 |
View Market Depth
| Last trade - 09.47am 05/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |
Day chart unavailable